From the Clinic to the Bench and Back Again in One Dog Year: How a Cross-Species Pipeline to Identify New Treatments for Sarcoma Illuminates the Path Forward in Precision Medicine

Cancer drug discovery is an inefficient process, with more than 90% of newly-discovered therapies failing to gain regulatory approval. Patient-derived models of cancer offer a promising new approach to identify new treatments; however, for rare cancers, such as sarcomas, access to patient samples is...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Sneha R., Somarelli, Jason A., Altunel, Erdem, Selmic, Laura E., Byrum, Mark, Sheth, Maya U., Cheng, Serene, Ware, Kathryn E., Kim, So Young, Prinz, Joseph A., Devos, Nicolas, Corcoran, David L., Moseley, Arthur, Soderblom, Erik, Hsu, S. David, Eward, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026496/
https://www.ncbi.nlm.nih.gov/pubmed/32117764
http://dx.doi.org/10.3389/fonc.2020.00117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026496/
https://www.ncbi.nlm.nih.gov/pubmed/32117764
http://dx.doi.org/10.3389/fonc.2020.00117

Ejemplares similares